I never state about patients are fearful its the doctors who will be fearful. The drug will not be easily prescribed unless someone fails both tasigna and sprycel. Unless its t315i all the mutations can be covered by the other TKIs some by tasina some by sprycel. Take a look at the number of patients on iclusig when the label was second line and how many cotinued on it because there was no other choices. There were about 600 patients who were on inclusig before withdrawl 260 continued to stay on the drug trough NDA. And only 90 new NDA in 2 months. The number suggest to me the market for salvage therapy is much smaller than the 13000 opportunity mentioned in CC.
Market Data 
Markets 
AI
